| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/10/2007 | CN1294142C 17 beta-carbothioate 17 alpha-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| 01/10/2007 | CN1294141C 6 alpha., 9 alpha-difluoro-17.alpha.-[(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
| 01/10/2007 | CN1294135C Pyrrolopyrimidines as protein kinase inhitibors |
| 01/10/2007 | CN1294133C Imidazo-pyrimidine derivatives as ligands for GABA receptors |
| 01/10/2007 | CN1294131C Pyrimidine compound |
| 01/10/2007 | CN1294126C N-phenyl-arylsulfonamide compound, drug comprising the compound as active ingredient, intermediate for the compound and preparation method thereof |
| 01/10/2007 | CN1294120C Pyrrolidinyl metalloprotease inhibitor and its application |
| 01/10/2007 | CN1294117C Amidino compound and salts thereof useful as nitric oxide synahase inhibitors |
| 01/10/2007 | CN1293917C DNA vaccine against proliferating endothelial cells and application thereof |
| 01/10/2007 | CN1293909C Granule with ginseng and astragalus root and preparation technique thereof |
| 01/10/2007 | CN1293888C Freeze dried powder injection of dandehon herb and its preparation process |
| 01/10/2007 | CN1293880C Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
| 01/10/2007 | CN1293878C Preventing or therapeutic agent for eye fatigue and pseudomyopia |
| 01/10/2007 | CN1293876C New use of 1,3-propylene glycol derivative |
| 01/10/2007 | CN1293875C Cell growth regulating factor S and its preparation process |
| 01/10/2007 | CN1293865C Cell growth regulating factor R and its preparation process |
| 01/09/2007 | US7161009 Antiinflammatory agents; skin disorders; central nervous system disorders |
| 01/09/2007 | US7161002 Compounds as antiinflammartory agents, antiproliferation agents and and anticancer agents from cyclodehydration of compounds |
| 01/09/2007 | US7160982 Peptide substrate identified by type BoNT/B botulinus toxin and use thereof for assaying and/or detecting said toxin or corresponding inhibitors |
| 01/09/2007 | US7160981 Peptide antagonists of DP transcription factors |
| 01/09/2007 | US7160923 Polyamine analogues as therapeutic and diagnostic agents |
| 01/09/2007 | US7160922 Biphenyl-4-carboxylic acid-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino)-2-hydroxyindan-1-yl)amide; cognitive activators, attention deficit/hyperactivity disorder, obesity, Alzheimer's disease, psychoses, schizophrenia; hypotensive agents for glaucoma |
| 01/09/2007 | US7160914 Compounds that exhibit specific molecular recognition of mixed nucleic acid sequences and bind in the DNA minor groove as a dimer |
| 01/09/2007 | US7160909 Cyclopenta[b]indole derivatives as sPLA2 inhibitors |
| 01/09/2007 | US7160905 Hydroxyethylene compounds with Asp2 inhibitory activity |
| 01/09/2007 | US7160904 Nicotine in therapeutic angiogenesis and vasculogenesis |
| 01/09/2007 | US7160903 Sulfonylaminocarboxylic acids |
| 01/09/2007 | US7160900 Tetrahydropyridino or piperidino heterocyclic derivatives |
| 01/09/2007 | US7160895 Inhibiting the proliferation of tumor cells, using 6-chloro-1,9-dimethyl-3-phenyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; anticancer treatment |
| 01/09/2007 | US7160894 Antagonist of phosphorylation of myosin regulatory light chain, enzyme inhibitors; therapeutic treatment of glaucoma, bronchial asthma, chronic obstructive pulmonary disease, nervous system disorders; 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamine |
| 01/09/2007 | US7160892 Pyrimidone compounds and pharmaceutical compositions containing the same |
| 01/09/2007 | US7160889 Quinazoline compounds |
| 01/09/2007 | US7160883 Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| 01/09/2007 | US7160879 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues |
| 01/09/2007 | US7160877 Aliphatic nitrogen-containing 5-membered ring compound |
| 01/09/2007 | US7160874 Phenylalanine derivatives |
| 01/09/2007 | US7160870 Thrombopoietin mimetics |
| 01/09/2007 | US7160863 Fusion protein contains amino acid sequence with 9 to 13 residues of arginine; antagonist of Nuclear Factor Activated T cell (NFAT); short effectiveness and no side effects or antigenicity; signal sequence, immunosuppressants, biodrugs |
| 01/09/2007 | US7160860 Biosynthesis inhibition of oestrogen in an oestrogen-dependent breast tumor by administering a antitumor biodrug, Sant 7; aromatase, oestrone sulphatase, or oestradiol dehydrogenase inhibitors |
| 01/09/2007 | US7160724 Cells for use in the treatment of nervous system disorders |
| 01/09/2007 | US7160722 Master bone formation transcription factor: compositions and methods of use |
| 01/09/2007 | US7160684 Methods of selecting compounds for modulation of bladder function |
| 01/09/2007 | US7160559 Galantamine hydrobromide particles and a water soluble film forming polymer are layered or coated on inert spheres, covered by a release rate controlling membrane made of a water insoluble polymer and optionally a plasticizer; galantamine and water-soluble polymer topcoat |
| 01/09/2007 | CA2407538C Novel bicyclic compounds |
| 01/09/2007 | CA2400801C Treatment of congestive heart failure by pretreated autologous blood |
| 01/09/2007 | CA2389325C 1-amino-alkylcyclohexane nmda receptor antagonists |
| 01/09/2007 | CA2340056C Pharmaceutical compositions containing lipase inhibitors |
| 01/09/2007 | CA2286190C Gnrh antagonists being modified in positions 5 and 6 |
| 01/09/2007 | CA2260790C Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
| 01/09/2007 | CA2260145C Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1 |
| 01/09/2007 | CA2194352C Diagnostic methods and compositions relating to the proteoglycan proteins of cartilage breakdown |
| 01/09/2007 | CA2186844C Use of serotonin antagonists (5ht3) for treating fibromyalgia |
| 01/09/2007 | CA2184262C Hygienic and cosmetic preparations for preventing and treating skin-diseases as well as a process for obtaining same |
| 01/09/2007 | CA2176511C Biologically active silicon compounds and their therapeutic and cosmetic applications |
| 01/09/2007 | CA2169831C Cosmetic melanins |
| 01/09/2007 | CA2159988C Novel deoxygalactonojirimycin derivatives |
| 01/08/2007 | WO2007007686A1 Composition for prevention of occurrence of cardiovascular event |
| 01/04/2007 | WO2007001049A1 Benzenoid ansamycin derivative |
| 01/04/2007 | WO2007000928A1 Remedy and/or preventive for chronic heart failure |
| 01/04/2007 | WO2007000924A1 Pharmaceutical composition comprising substance capable of inhibiting or promoting progranulin activity and screening method for substance capable of inhibiting or promoting progranulin activity |
| 01/04/2007 | WO2007000884A1 Prophylactic/therapeutic agent for bone/joint disease and screening method for the agent |
| 01/04/2007 | US20070004807 Methods using phenethanolamine derivatives for treatment of respiratory diseases |
| 01/04/2007 | US20070004806 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
| 01/04/2007 | US20070004800 Oral and rectal drug delivery of a mixture of 4-aminophenylacetic acid and 5-aminosalicylic acid; antiinflammatory agents for gastrointestinal tract; antiulcer agents |
| 01/04/2007 | US20070004791 (1 alpha ,5 alpha ,6 alpha )-N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2,2-diphenyl acetamide; high affinity towards Muscarinic 3 receptors; avoiding adverse side effects; for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems |
| 01/04/2007 | US20070004780 Administering 2 to 8 mg per day of nontoxic insulin sensitiser rosiglitazone, and 500 mg or 850 mg of biguanide antihyperglycaemic agent; Type II diabetes |
| 01/04/2007 | US20070004764 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective |
| 01/04/2007 | US20070004755 Inhibiting the proteolytic activity of cathepsin S; 1-[4-(5-Chloro-1H-indol-3-yl)-piperazine-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2-ol; antiarthritic agent; autoimmune disease: lupus, rheumatoid arthritis, and asthma |
| 01/04/2007 | US20070004754 Substituted pyrazoles |
| 01/04/2007 | US20070004747 Substituted pyrazoles |
| 01/04/2007 | US20070004746 Imatinib mesylate; antitumor agent |
| 01/04/2007 | US20070004740 phosphodiesterase 4 inhibitors which are naphthalene compounds such as 6,7-Dimethoxy-1-[2-(1,3-dioxocyclohexan-2-yl)pyridin-4-yl]-2,3-bis(hydroxymethyl)naphthalene; asthma or inflammatory diseases |
| 01/04/2007 | US20070004739 Condensed polycyclic compounds |
| 01/04/2007 | US20070004738 Substituted pyrazoles |
| 01/04/2007 | US20070004736 Imidazole derivative, process for producing the same, and use |
| 01/04/2007 | US20070004716 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient |
| 01/04/2007 | US20070004703 Use of 1-(dialkoxyphenylsulfonyl)-3-(pyrrolidino)-3-(phenyl)indolin-2-one compounds to treat hypertension, cardiovascular disorders, central nervous system disorders, psychological disorders, gastrointestinal disorders; affinity for V1b and V1a receptors of arginine-vasopressin |
| 01/04/2007 | US20070004674 Remedy for diseases associated with immunoglobulin gene translocation |
| 01/04/2007 | US20070004669 Mono-, di- or trifluoromethyl derivatives, e.g., 6-amino-9-(2-C-fluoromethyl- beta -D-ribofuranosyl)purine, 2'-C-(fluoromethyl)-5-methylcytidine and 2-amino-9-(2-C-fluoromethyl- beta -D-ribofuranosyl)-3,9-dihydropurin-6-thione; used to treat a hepatitis C virus infection |
| 01/04/2007 | US20070004650 Endurance improving agent |
| 01/04/2007 | US20070004637 Alzheimer's disease; for promoting secretion of amyloid precursor protein-alpha (sAPP), neurodegenerative disease, neuropathy in cerebrovascular disease, head trauma, spinal damage, encephalitis sequela, or cerebral palsy, memory disorder |
| 01/04/2007 | US20070004630 Treating cell proliferation disease; aberrant fetoplacental growth; cancer |
| 01/04/2007 | US20070004012 Reacting chondroitin disaccharide with a recombinantly produced 2-O sulfatase; using 2-O sulfatase for degrading and analyzing glycosaminoglycans (GAGs) present in a sample |
| 01/04/2007 | US20070004009 Methods for making recombinant proteins using apoptosis inhibitors |
| 01/04/2007 | US20070004005 Tendon-inducing compositions |
| 01/04/2007 | US20070003963 RNA sequence-specific mediators of RNA interference |
| 01/04/2007 | US20070003962 Used in targeting specific mRNAs for degradation in mammalian cells where use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response |
| 01/04/2007 | US20070003961 Used in targeting specific mRNAs for degradation in mammalian cells where use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response |
| 01/04/2007 | US20070003960 Producing knockdown cells; Used in targeting specific mRNAs for degradation in mammalian cells where use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response |
| 01/04/2007 | US20070003642 Composition containing high concentration of isoflavone and having high solubility and process for producing the same |
| 01/04/2007 | US20070003571 Modified herpes simplex viral particle for targeting and destroying tumor cells |
| 01/04/2007 | US20070003556 Modified antibodies against cd22 and utilization thereof |
| 01/04/2007 | US20070003548 Anti-TNF antibodies, compositions, methods and uses |
| 01/04/2007 | US20070003544 Combination therapy for treatment of autoimmune diseases using b- cell depleting/immunoregulatory antibody combination |
| 01/04/2007 | US20070003533 Inhibition of the beta3 subunit of L-type Ca2+ channels |
| 01/04/2007 | CA2613632A1 Benzenoid ansamycin derivative |
| 01/04/2007 | CA2613126A1 Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases |
| 01/03/2007 | EP1739186A1 Method of screening compound capable of accelerating or inhibiting apoptosis, apoptosis accelerator and apoptosis inhibitor |
| 01/03/2007 | EP1739177A1 Antibodies against interferon alpha/beta receptor |
| 01/03/2007 | EP1739087A1 Pyrazole compositions useful as inhibitors of gsk-3 |